{"groups":[{"description":"Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days. Treatment continues until disease progression or unacceptable toxicity.","id":"FG000","title":"Ribociclib and Letrozole"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Eligible with no protocol therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"51"}],"comment":"Enrolled and eligible","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"comment":"Eligible and treated","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 74 participants were screened for eligibility in the study. Out of these, 51 participants were determined to be eligible for enrollment. The recruitment period spanned from June 2018 to February of 2023.The first patient was enrolled on May 20, 2019."}